# Patatin‐domain‐containing (phospho)lipases under control: Mammalian co‐regulators and pathogenic activation mechanisms

**Authors:** Noopur Dubey, Lina Riegler‐Berket, Monika Oberer

PMC · DOI: 10.1002/2211-5463.70201 · 2026-01-31

## TL;DR

This paper reviews the structure and function of patatin-like phospholipases, focusing on how they are activated through protein interactions and their roles in health and disease.

## Contribution

The paper identifies conserved structural elements (D-segment and regulatory segment) that modulate enzyme activity through co-activation mechanisms.

## Key findings

- Structural analysis reveals conserved segments that modulate active-site architecture in patatin-like phospholipases.
- Protein–protein interactions and conformational changes are critical for enzyme activation and regulation.
- PNPLA proteins show diverse biological roles and regulatory mechanisms across species.

## Abstract

Patatin‐like phospholipase (PNPLA) domain‐containing proteins are essential enzymes involved in lipid metabolism, membrane remodeling, and signaling pathways across various organisms. This review focuses on the structural and functional characteristics of four selected PNPLA proteins from different organisms with experimental 3D structures or biochemical data on protein–protein interactions that facilitate their co‐activation mechanism, namely VipD, ExoU, PNPLA9, and PNPLA2 (also known as ATGL). VipD and ExoU, phospholipases from Legionella pneumophila and Pseudomonas aeruginosa, respectively, are multidomain proteins and utilize distinct mechanisms for host cell interaction and pathogenesis. VipD binds to Rab proteins, underscoring the critical role of Rab5 in upregulating its enzymatic activity and contributing to the pathogenicity. ExoU requires ubiquitin for activation and exhibits an inhibited structure when complexed with its chaperone SpcU. PNPLA9, a calcium‐independent phospholipase A2, is predominantly expressed in the human brain, with mutations linked to neurodegenerative disorders and inflammation. The crystal structure of the Chinese hamster ortholog of PNPLA9 reveals a dimerization mechanism required for its catalytic activity, along with specific regions identified for membrane interaction and substrate binding. PNPLA2 is known for its triacylglycerol hydrolytic activity and is regulated by protein–protein interactions, particularly with the co‐activator ABHD5, which is crucial for its activation. This review highlights the diversity and conserved architectural segments of PNPLA proteins, reflecting their varied biological roles and regulatory mechanisms. Understanding the diverse protein–protein interactions that activate these enzymes is crucial for elucidating their roles in physiological and pathological contexts.

Patatin domain‐containing (phospho)lipases are lipid‐hydrolyzing enzymes central to metabolism, membrane remodeling, and signaling. Their activity relies on precise co‐activation mechanisms involving protein–protein interactions and conformational rearrangements. Structural analysis reveals two key elements, named the D‐segment and the regulatory segment, that dynamically modulate active‐site architecture, control access to the substrate‐binding cavity, and enable formation of fully competent catalytic proteins.

## Linked entities

- **Genes:** vipD (Dot/Icm type IV secretion system effector VipD) [NCBI Gene 57036829], exoU (succinoglycan biosynthesis glycosyltransferase ExoU) [NCBI Gene 89577828], PLA2G6 (phospholipase A2 group VI) [NCBI Gene 8398], PNPLA2 (patatin like domain 2, triacylglycerol lipase) [NCBI Gene 57104], PNPLA2 (patatin like domain 2, triacylglycerol lipase) [NCBI Gene 57104], ABHD5 (abhydrolase domain containing 5, lysophosphatidic acid acyltransferase) [NCBI Gene 51099], RAB5A (RAB5A, member RAS oncogene family) [NCBI Gene 5868], CG11700 (uncharacterized protein) [NCBI Gene 31564]
- **Proteins:** vipD (Dot/Icm type IV secretion system effector VipD), exoU (succinoglycan biosynthesis glycosyltransferase ExoU), PLA2G6 (phospholipase A2 group VI), PNPLA2 (patatin like domain 2, triacylglycerol lipase), PNPLA2 (patatin like domain 2, triacylglycerol lipase), ABHD5 (abhydrolase domain containing 5, lysophosphatidic acid acyltransferase), RAB5A (RAB5A, member RAS oncogene family)
- **Species:** Legionella pneumophila (taxon 446), Pseudomonas aeruginosa (taxon 287), Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** G0S2 (G0/G1 switch 2) [NCBI Gene 50486], PLA2G6 (phospholipase A2 group VI) [NCBI Gene 8398] {aka CaI-PLA2, GVI, INAD1, IPLA2-VIA, NBIA2, NBIA2A}, PNPLA3 (patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase) [NCBI Gene 80339] {aka ADPN, C22orf20, iPLA(2)epsilon}, DNAJC5 (DnaJ heat shock protein family (Hsp40) member C5) [NCBI Gene 80331] {aka CLN4, CLN4B, CSP, DNAJC5A, mir-941-2, mir-941-3}, CA2 (carbonic anhydrase 2) [NCBI Gene 760] {aka CA-II, CAC, CAII, Car2, HEL-76, HEL-S-282}, PLA2G1B (phospholipase A2 group IB) [NCBI Gene 5319] {aka PLA2, PLA2A, PPLA2}, MBOAT2 (membrane bound glycerophospholipid O-acyltransferase 2) [NCBI Gene 129642] {aka LPAAT, LPCAT, LPEAT, LPLAT 2, LPLAT13, OACT2}, FABP4 (fatty acid binding protein 4) [NCBI Gene 2167] {aka A-FABP, AFABP, ALBP, HEL-S-104, aP2}, ABHD5 (abhydrolase domain containing 5, lysophosphatidic acid acyltransferase) [NCBI Gene 51099] {aka CGI58, IECN2, NCIE2}, LIPE (lipase E, hormone sensitive type) [NCBI Gene 3991] {aka AOMS4, FPLD6, HSL, LHS, REH}, CTD (Coats disease) [NCBI Gene 1283], LIPF (lipase F, gastric type) [NCBI Gene 8513] {aka GL, HGL, HLAL}, AGFG1 (ArfGAP with FG repeats 1) [NCBI Gene 3267] {aka HRB, RAB, RIP}, RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, HILPDA (hypoxia inducible lipid droplet associated) [NCBI Gene 29923] {aka C7orf68, HIG-2, HIG2}, PNPLA1 (patatin like domain 1, omega-hydroxyceramide transacylase) [NCBI Gene 285848] {aka ARCI10, dJ50J22.1}, RAB5A (RAB5A, member RAS oncogene family) [NCBI Gene 5868] {aka RAB5}, PLAAT1 (phospholipase A and acyltransferase 1) [NCBI Gene 57110] {aka A-C1, H-REV107, HRASLS, HRASLS1, HRSL1, HSD28}, PLIN1 (perilipin 1) [NCBI Gene 5346] {aka FPLD4, PERI, PLIN}, PNPLA2 (patatin like domain 2, triacylglycerol lipase) [NCBI Gene 57104] {aka 1110001C14Rik, ATGL, FP17548, PEDF-R, TTS-2.2, TTS2}, PLA2G4A (phospholipase A2 group IVA) [NCBI Gene 5321] {aka GURDP, PLA2G4, cPLA2, cPLA2-alpha}, CALM1 (calmodulin 1) [NCBI Gene 801] {aka CALML2, CAM2, CAM3, CAMB, CAMC, CAMI}
- **Diseases:** insulin resistance (MESH:D007333), Hypoxia (MESH:D000860), T3SS (MESH:C536044), necrosis (MESH:D009336), inflammation (MESH:D007249), infection (MESH:D007239), neurodegenerative disorders (MESH:D019636), sepsis (MESH:D018805), MLD (MESH:D015433), toxicity (MESH:D064420)
- **Chemicals:** Deuterium (MESH:D003903), ester (MESH:D004952), cardiolipins (MESH:D002308), polyunsaturated fatty acid (MESH:D005231), Ser (MESH:D012694), phosphatidylcholine (MESH:D010713), ATP (MESH:D000255), Asp (MESH:D001224), lysophospholipid (MESH:D008246), phospholipid (MESH:D010743), retinyl esters (MESH:D000084562), oleic acid (MESH:D019301), acyl-CoA (MESH:D000214), alcohol (MESH:D000438), TAG (MESH:D014280), Hydrogen (MESH:D006859), water (MESH:D014867), Lipid (MESH:D008055), GTP (MESH:D006160), calcium (MESH:D002118), fatty acid (MESH:D005227), acylglycerols (MESH:D005989), Phosphatidylinositol 4,5-bisphosphate (MESH:D019269), DOC130 (-), thiol (MESH:D013438), free fatty acid (MESH:D005230), PI3P (MESH:C055525), Gly (MESH:D005998)
- **Species:** Pseudomonas fluorescens (species) [taxon 294], Mus musculus (house mouse, species) [taxon 10090], Cricetulus griseus (Chinese hamster, species) [taxon 10029], Pseudomonas aeruginosa (species) [taxon 287], Homo sapiens (human, species) [taxon 9606], Pseudomonas fluorescens A506 (strain) [taxon 1037911], Legionella pneumophila (species) [taxon 446], Cricetus cricetus (black-bellied hamster, species) [taxon 10034], Solanum cardiophyllum (heartleaf nightshade, species) [taxon 160510]
- **Mutations:** Asn39, Glu96-Ser101, I148M, Val70, A 180, Leu62Lys, Met348, Ile70Ala, Phe348Glu, Pro86Lys, Trp695, Asn39Glu, Asn180, Gly189, Met611 with a glycine, Trp695Glu, Leu261Glu, Leu102, Leu159Ala, 220 residues C, Leu159, Pro156Lys, Gln180, Leu102Lys, Pro156, Leu261, Arg351Leu, Leu62, Asn180Leu, Ile70, Pro258Leu, Pro258, Gly189Glu, Lys275Ala

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12871566/full.md

---
Source: https://tomesphere.com/paper/PMC12871566